Protein Supplementation in Thiazide-induced Hyponatremia
NCT02614807 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL
Last updated 2018-09-10
Summary
High blood pressure is very common among elderly Canadians. Clinical trials show clear benefit from lowering blood pressure in hypertensive elderly patients. These trials also demonstrate safety for several classes of blood pressure lowering drugs including water pills. However, water pills (thiazide diuretics) used for treatment of hypertension, can cause low sodium (hyponatremia), a significant clinical problem mainly among elderly and very elderly. Causes are age related decrease in kidneys' ability to get rid of water and low salt coupled with high water intake. A standard approach to treatment is lacking since higher salt intake may worsen hypertension, and lower water and higher protein intake is difficult to understand and actually implement. 'Nepro' is a nutritional drink high in protein, and low in potassium and sodium. It is used frequently as a dietary supplement in patients with kidney disease specifically for low sodium and high protein content. The high protein content in Nepro can help the kidney get rid of excess water, and the low sodium and potassium content will make this a safe option to use. Hence investigators propose a proof-of-concept trial on an easy to understand and administer, and relatively affordable solution to this issue. It could be summarized in one sentence: "Will a bottle of Nepro a day keep thiazide-caused hyponatremia and the doctor away?"
Conditions
- Hyponatremia
- Hypertension
- Blood Pressure
Interventions
- DIETARY_SUPPLEMENT
-
Nepro
The intervention is a dietary protein supplement. In the elderly hypertensive patient (assuming body weight of 70 kg) with mild to moderate hyponatremia free water excess is around 2.5 L. One bottle of Nepro/day will generate about 120 mosm to be excreted via urine. Given limited and mostly fixed urinary dilution and concentration between 300 and 800 mosm/L in the elderly and very elderly, one bottle of Nepro a day will result in an extra 400 ml of urine for a net loss of 163 ml of free water. Thus over the period of 2 to 4 weeks the calculated free water excess should be completely eliminated.
Sponsors & Collaborators
-
Ottawa Hospital Research Institute
lead OTHER
Principal Investigators
-
Marcel Ruzicka, MD PhD · Ottawa Hospital Research Institute
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-06-30
- Primary Completion
- 2018-05-31
- Completion
- 2018-05-31
Countries
- Canada
Study Locations
More Related Trials
-
Fractional Urate Excretion in Nonedematous Hyponatremia
NCT01425125 ·Status: WITHDRAWN ·Phase: NA
-
Trial Assessing the Effect of Preoperative Furosemide on Intraoperative Blood Pressure
NCT00115726 ·Status: COMPLETED ·Phase: PHASE4
-
Urea for Chronic Hyponatremia
NCT04588207 ·Status: TERMINATED ·Phase: PHASE2
-
Sodium Diet Effect on Aldosterone and Urinary RNA (SALTY)
NCT04168073 ·Status: COMPLETED ·Phase: NA
-
Steroids on Intra-dialytic Hypotension
NCT03465007 ·Status: COMPLETED ·Phase: NA
-
DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease
NCT02875886 ·Status: COMPLETED ·Phase: PHASE4
-
Diuretic Comparison Project
NCT02185417 ·Status: COMPLETED ·Phase: PHASE3
-
Protein Supplementation in Hyponatremia Due to the Syndrome of Inappropriate Antidiuresis
NCT06821802 ·Status: RECRUITING ·Phase: NA
-
Tissue Sodium in Pre-hypertensive Patients
NCT02236520 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of Hydrochlorothiazide in the Treatment of Hypernatremia in Critically Ill Patients
NCT03658850 ·Status: UNKNOWN ·Phase: PHASE2
-
Sodium Lowering and Urinary Protein Reduction Trial
NCT02945969 ·Status: COMPLETED ·Phase: PHASE3
-
Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Oral Lixivaptan Capsules in Subject With Euvolemic Hyponatremia
NCT00660959 ·Status: COMPLETED ·Phase: PHASE3
-
Sodium-restricted Diets and Symptoms in End Stage Renal Disease: An RCT
NCT02778516 ·Status: COMPLETED ·Phase: NA
-
Effect of Statin Use on Aldosterone Secretion
NCT02871687 ·Status: COMPLETED ·Phase: PHASE1
-
The Effect of Thiazide, Amiloride and Hypertonic Saline on Urinary Biomarkers in Healthy Subjects
NCT01635231 ·Status: COMPLETED ·Phase: NA
-
Low-dose Tolvaptan for Inpatient Hyponatraemia.
NCT06171100 ·Status: RECRUITING
-
Asymptomatic Bacteriuria, Hyponatremia and Geri-atric Syndrome
NCT05055856 ·Status: COMPLETED ·Phase: NA
-
Double Blind Crossover Comparison of Diuretics in the Young
NCT00429897 ·Status: UNKNOWN ·Phase: NA
-
Protocolized Diuretic Strategy in Cardiorenal Failure
NCT01921829 ·Status: TERMINATED ·Phase: PHASE4
-
Concentrated Saline Infusions and Increased Dietary Sodium With Diuretics for Heart Failure With Kidney Dysfunction
NCT00575484 ·Status: TERMINATED ·Phase: PHASE2
-
The Clinical and Laboratory Characteristics of Recurrent Drug- Related Hyponatremia
NCT01509170 ·Status: UNKNOWN
-
Preventing Metabolic Side Effects of Thiazide Diuretics With KMgCitrate
NCT02665117 ·Status: COMPLETED ·Phase: NA
-
Dietary Sodium Restriction in Hemodialysis Patients
NCT01896882 ·Status: UNKNOWN ·Phase: NA
-
The Effect of Amiloride and Spironolactone in Patients With Hypertension
NCT01388088 ·Status: COMPLETED ·Phase: PHASE4
-
International, Multicenter, Open-Label and Randomized Withdrawal Study of Oral Lixivaptan in Heart Failure Patients With Chronic Hyponatremia
NCT00876876 ·Status: WITHDRAWN ·Phase: PHASE3